• Sana Biotechnology swung to third-quarter 2026 net income of $20.4 million from a year-earlier loss of $42.2 million.
• Non-cash gains from revaluing success-payment liabilities and contingent consideration totaled $63.4 million, primarily reflecting an amendment to the Cobalt acquisition agreement.
• Cash, cash equivalents and marketable securities totaled $121.7 million at September 30, with expected cash runway into mid-2027.
• Clinical studies of diabetes therapy SC451 and lymphoma treatment SG293 are expected to begin later in 2026 and in first-quarter 2027, respectively.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sana Biotechnology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611051605PRIMZONEFULLFEED9871647) on November 05, 2026, and is solely responsible for the information contained therein.